Brief: Affimed presents final data for AFM13 phase 1 trial
08/12/2014 10:06
Dec 8 (Reuters) - Affimed NV AFMD.O : * Presents final data for AFM13 phase 1 trial at ASH * Says analyses confirmed results reported to date that AFM13 is well tolerated with a favorable administration profile * Source text for Eikon ID:nGNXVCGPUa * Further company coverage AFMD.O ((Bengaluru Newsroom; +1 646 223 8780))
Recent news on Affimed NV
See all newsBrief: Affimed Announces Receipt Of Nasdaq Delisting Notice
Brief: Affimed Announces Receipt Of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
Brief: Affimed Reports Positive Clinical Update On Afm24/Atezolizumab Combination Therapy
Brief: Affimed NV Files For Common Stock Offering Of Up To $20 Million - SEC Filing
Brief: Affimed NV Files For Mixed Shelf Offering Of Up To $20 Million